[
  {
    "request": {
      "base_url": "https://openrouter.ai/api/v1",
      "model": "openai/gpt-5-mini",
      "messages": [
        {
          "role": "user",
          "content": "Your outpatient, who has PTSD, a questionable chart hx of bipolar II d/o, cocaine use d/o in remission, and alcohol use d/o in remission, at the COH smokes a large amount of cannabis every day and doesn\u2019t think there is a problem with it. He states that cannabis is the \u201conly thing that works\u201d for anxiety, adding that \u201ceverything else I\u2019ve tried doesn\u2019t work.\u201d He has been struggling mightily with insomnia. His meds (\u201cnone of them are working!\u201d- the patient) include sertraline 100 mg BID , venlafaxine 225 mg qD, for mood/PTSD sx, aripiprazole 5 mg BID for bipolar , prazosin 1mg qHS for nightmares, acamprosate 666 mg TID for AUD, naltrexone 50 mg qdaily for AUD, hydroxyzine 25 mg qHS PRN for anxiety , atomoxetine 80 mg qD for questionable ADHD symptoms. The patient is asking for stimulants for ADHD.\n\nGiven the patient's complex psychiatric and substance use history, which three of the following treatment options should be prioritized immediately to address his current challenges?\nI. Counsel patient on stopping cannabis.\nII. Ask patient to request admission to the hospital so he can be detoxed off all of his psych meds.\nIII. Order a urine drug test.\nIV. Prescribe melatonin for insomnia.\nV. Discontinue acamprosate and increase dosage of naltrexone for AUD.\nVI. Start atomoxetine.\n\nAnswer Choices:\nA. I, II, III\nB. I, II, IV\nC. I, II, V\nD. I, II, VI\nE. II, III, IV\nF. II, III, V\nG. II, III, VI\nH. II, IV, V\nI. II, IV, VI\nJ. III, IV, V\nK. III, IV, VI\nL. I, III, IV\nM. I, III, V\nN. I, III, VI\nO. I, IV, V\nP. I, IV, VI\nQ. II, V, VI\nR. III, V, VI"
        }
      ],
      "reasoning_effort": "medium",
      "response_format": {
        "type": "json_schema",
        "json_schema": {
          "name": "answer",
          "strict": true,
          "schema": {
            "type": "object",
            "properties": {
              "answer": {
                "type": "string"
              },
              "answer_letter": {
                "type": "string",
                "enum": [
                  "A",
                  "B",
                  "C",
                  "D",
                  "E",
                  "F",
                  "G",
                  "H",
                  "I",
                  "J",
                  "K",
                  "L",
                  "M",
                  "N",
                  "O",
                  "P",
                  "Q",
                  "R"
                ]
              }
            },
            "required": [
              "answer",
              "answer_letter"
            ],
            "additionalProperties": false
          }
        }
      },
      "usage": {
        "include": true
      }
    },
    "response": {
      "id": "gen-1762208073-oZS4MjgjjUgB0TxvSaOV",
      "choices": [
        {
          "finish_reason": "stop",
          "index": 0,
          "logprobs": null,
          "message": {
            "content": "{\"answer\":\"L. Prioritize: I (counsel patient to stop cannabis), III (order a urine drug test), and IV (trial melatonin for insomnia).\\n\\nRationale: This patient is daily heavy cannabis\u2011using with PTSD/insomnia and a substance\u2011use history \u2014 immediate counseling about cannabis harms and treatment options is appropriate. A urine drug screen is useful to confirm recent use, check for other substances, and guide safety/medication decisions. Melatonin is a low\u2011risk, non\u2011addictive first-line adjunct for insomnia and preferable to prescribing sedative/habit\u2011forming agents or stimulants. Options like inpatient \u201cdetox\u201d off all psych meds, starting stimulants/atomoxetine, or arbitrarily changing AUD meds are not immediate, evidence\u2011based steps in this scenario.\",\"answer_letter\":\"L\"}",
            "refusal": null,
            "role": "assistant",
            "annotations": null,
            "audio": null,
            "function_call": null,
            "tool_calls": null,
            "reasoning": "**Evaluating treatment options**\n\nI need to pick three treatment options to prioritize for a patient who uses cannabis daily and thinks it's helping with anxiety. Their current medications include sertraline, venlafaxine, aripiprazole, prazosin, acamprosate, and naltrexone, which raises a few questions about their combined use. The patient is also asking for stimulants. Given the complex history, I think option I\u2014counseling the patient on stopping cannabis\u2014would be a good starting point to address the current challenges.**Prioritizing treatment options**\n\nI need to evaluate treatment options for the patient. Asking for hospital admission to detox from all psych meds seems inappropriate; detoxing isn\u2019t necessary. However, I think ordering a urine drug test is a good idea to confirm substance use and adherence. Prescribing melatonin for insomnia could also be reasonable since it's non-addictive and might help him without adding more sedatives into the mix. I\u2019m not sure about discontinuing acamprosate; it\u2019s worth considering the evidence on combining it with naltrexone for alcohol use disorder.**Selecting treatment priorities**\n\nI\u2019m evaluating acamprosate and naltrexone; while they can be prescribed together, it's not standard practice. I\u2019m not sure if increasing naltrexone above 50 mg is necessary either. Starting atomoxetine seems off since the patient is already on it and adding stimulants would be inappropriate due to their history. I think the best options to prioritize are counseling the patient on stopping cannabis, ordering a urine drug test, and prescribing melatonin for insomnia. I\u2019ll also want to double-check for any polypharmacy interactions.**Finalizing treatment rationale**\n\nI\u2019m checking my answer choices: L, which includes I, III, and IV. I\u2019m feeling good about this selection. I will counsel the patient on the harms of cannabis, especially regarding their PTSD and insomnia. A urine drug test will confirm substance use and medication adherence, while melatonin is safe and non-addictive for insomnia. I want to avoid starting stimulants due to the patient\u2019s substance use history and the risks associated with bipolar disorder. No need to hospitalize for detox or make sudden changes to alcohol use disorder medications. I\u2019ll prepare the final response in JSON format with the answer letter \"L.\"",
            "reasoning_details": [
              {
                "type": "reasoning.summary",
                "summary": "**Evaluating treatment options**\n\nI need to pick three treatment options to prioritize for a patient who uses cannabis daily and thinks it's helping with anxiety. Their current medications include sertraline, venlafaxine, aripiprazole, prazosin, acamprosate, and naltrexone, which raises a few questions about their combined use. The patient is also asking for stimulants. Given the complex history, I think option I\u2014counseling the patient on stopping cannabis\u2014would be a good starting point to address the current challenges.**Prioritizing treatment options**\n\nI need to evaluate treatment options for the patient. Asking for hospital admission to detox from all psych meds seems inappropriate; detoxing isn\u2019t necessary. However, I think ordering a urine drug test is a good idea to confirm substance use and adherence. Prescribing melatonin for insomnia could also be reasonable since it's non-addictive and might help him without adding more sedatives into the mix. I\u2019m not sure about discontinuing acamprosate; it\u2019s worth considering the evidence on combining it with naltrexone for alcohol use disorder.**Selecting treatment priorities**\n\nI\u2019m evaluating acamprosate and naltrexone; while they can be prescribed together, it's not standard practice. I\u2019m not sure if increasing naltrexone above 50 mg is necessary either. Starting atomoxetine seems off since the patient is already on it and adding stimulants would be inappropriate due to their history. I think the best options to prioritize are counseling the patient on stopping cannabis, ordering a urine drug test, and prescribing melatonin for insomnia. I\u2019ll also want to double-check for any polypharmacy interactions.**Finalizing treatment rationale**\n\nI\u2019m checking my answer choices: L, which includes I, III, and IV. I\u2019m feeling good about this selection. I will counsel the patient on the harms of cannabis, especially regarding their PTSD and insomnia. A urine drug test will confirm substance use and medication adherence, while melatonin is safe and non-addictive for insomnia. I want to avoid starting stimulants due to the patient\u2019s substance use history and the risks associated with bipolar disorder. No need to hospitalize for detox or make sudden changes to alcohol use disorder medications. I\u2019ll prepare the final response in JSON format with the answer letter \"L.\"",
                "format": "openai-responses-v1",
                "index": 0
              },
              {
                "type": "reasoning.encrypted",
                "data": "gAAAAABpCSlbwCTyFGMSZu9MAOdE6N915HZfiXLQMQzMwO0JlLH_Uz09mdp4DCrZ1GKG9ZdYpNi2wJdxb7QLIi2Lmrh1jZHx1VtOnC0hCErG7eUSpGqGevufijlvrfVML40JByd3YbKPiPuDWWFIMmIyeitvaU1IBbC-gEY5bPxMnbORv4FAwABQ5hkmytetR6jEw-FjgrakCgIbNXseaA2XL_4FDjVfGPxP1fo8oJIPOJ3n2uNSuvFshlAVN0M-ABolxVk87YPmoAiomREQVuNUGYTW6TCSu3dpMf4MNJz4-eJYOntXq_xuZVqEJWjwer1aa0E7ML_xVHDyDJi98f_WlGPBE2Q5AgqRN-umRIH3z6oKRez_SWKvE-ZSSkXrVeQDcjAjs3aFdDMczYwy0BW6dBwQI8r6E8gjxHymfT2ecODnBVs2o3imEgZ4Do5E-wlwb984U9P2_PDrJXplNJWHnS6IdefAIzgfw-0z5DZ7qyolcsJ7INZ18W_mAkg33WAbQe1TIUH-AVnTGmdnrCl0bxuj35h6FSuzMMKOtFwqh2x70FXaIvndfw2i44g9FO7T78jLuj664lSt30wBXy2duKMs4RJQtnrmkNQceGcimVL3sMYjzUj3N2t64pomNdCAysp3gERFDpfqWWk7uQIqp0Wl9UlHtgAqOdj8Lk8-oj1kwb_JC448cYXZle0zQ3cwOncOt8HkzteUgDQ90YU5Bi-PBPCDPDBFOLSQ1BI-xMv8WrE7lHt-2ilzmV0ayIJWD_lv8QgJ5udAbG7bwlJlc1jALU_cL6Boz06Oa9UZGtvZoD-0TRTo3pwOgk7XSGd2QBja0lryv6ZhkaC8BthPJpiLAppdkOXT02E4LAP218SBcfHa6XSk3uYwxMUg0PN8PD_FysnnFTap286zSzoRqligRKhFeMvZneDb-nhYEMj3ONhdH4CejNHHyDUWTve5kznzKhJrTat81thvFb6ahQoyo-svRaLB51wQTxvnBxb_2mAWtI0DI3s4HXDpU6oPs8B6zL7lFaRUUGui29gF18l9KdURH7P6mnXHnq_OsRorRiC9WtJmkK3MGCX5FSBNnAgc1fU3jxbQemobLJWSfp9aycbdCFtX5jtfeeeTuxx_UxcOhksyEI4BLbMLANeEK8iktsJf2bnBykulBVzuf0WKfRjBc4THYETUYtnEHYMKQeGuT1RyAyUKgVZL1YuIZ_CR_owu8PRHSMMQFzYd0TZh7qHCVdU9qEJGHadsU726ekJePkqHM0zdopco0I9L42WWgVxov5b_7obePBmpfXMbpKhwyhxj5PvijUWXOueM9pXcCLY6T0d9imtYq0n9a3s2x0MQr7V3sx1GST30-s0F2tJeiYrw7swCHmtws9kBLHOt0plCu2Ve5k7fCoVP7VkTtL5KEd9-WfVK1lT26f_QM5fZ7rYgdGSutdemCpZaPxkcyaXTX2YaFZjM2kgQucK4Toj9n2LOVnQ2V8vyyD-aFzz0-HxBDTpR6CkWlpbwRZ3KSS_U-k7P_zuojj2VXtrIOskw3HP_jxtq4xFHbvHRe1I0uMMcry_Mcsx9uTDaiZcnPYpWSvf0eMURVq28MfQRPngjJP73EwB_CzqKGxc-SuYVil7g3byth7KOTYbOEjCh6Y4L6oyoPG6ci1pgzWL92WMZPTzUg8ECLzMOPNEiJbS7ZoXJ2ktBkxu6Wf0z3uMkTb8uuBtbhZmjBo47LHB1Kv7gbBZm0Qygb0JbuXzkGVp0nJVCQ0gPBah3Y2lsU0n6C7kbkfCAnOMAceEyx51KY7qEK3Do3Fayf-pri3wD3n49Iv_tQWX9OGGa3pf6FMbju7xZpOJXeXrzwySPNEodzHrkU3K6C_lDgXSLBM2zhQg1dG8TdTLGZTLjyDLFPpgTosLbAZLl0xRj2ZDvgsa3EzoKalwu6_BpHlj_9DVTlsq7TUd0UhZHi5pj4SmmT371ZzVWFaTQzzzdp-IwrNhsjkjhvins9vTarfnVc_9KBsuOnhMZPZV6mRZlk33nbIqkQEd9F_8FOwFfpZo09NYyFM_m7AnhbWATpEsHgoqSnzrs7DvyBT88VLDD0Jp0mkxSeOyYlKNSN2TW6vAaufn4Fs4Ct_jptfiN1UXHWBN_Zgw_bUZciWznYEv6tXQrlt7jVGsCcbaSTCR8TwbBN0vuKwkX1VZZfMdssvuVrAN9_qriV14eiCebM9egRB30ND0mQPegphsP59ZOZepYyxWQuabI3eQVd59OWzC19QT169oouzxKTqn3Uxp7BRPj7ke4tPPquMZy1Bno6LZhoScxH2iPhma61ZBq0DqvmG-qBogQwyGNFV3gizR2pVOk1GhWd5tqM4FoIqgydV2jsMSNQ-LwGKuu97aSBJf7UDxi2bBH2tC40ek2YFG6tXShN45DjOHVihlCbro60BWTdbG4FktjVNLtHiGWlG5oweC97IfSd_6lfPFfGI-V4NcCxC7JXo8x3I795Ovat_7YDSScvdPvgl6nFzoM495LHur2IcaAbnM5cjI8Z7__vpYWpEKRZS7uWD9vCTNxBSjoZPvVTjHcGzlS8mWwaIx8TN_qh300Yj_MwDq8dK3Z9T5VdI1oqkAJOisVssc1kz6PGrCokrUoorUTG_e1eqeu1DyglKpBrQ9TvssYW6oye3wW47ClDBJBrWdi_xZhFMpL6rs-Xl4Qt3AonGluA-clxFTAqyDLCAJAtU5h12UPZfYzbyytAzqPoG87fc9W-ZXSz9Jr41QL98RNbap77IfDFr9GZ2HE0aQf_JpcRfyj0GcGDxCESuGedWnXePJgK-sy8xK7_KcpwhJ760wQqtPFKb2w5nmtr3C3MygyJrW0oR1bdM6RHe6FlU1Er29wyPiwz1VMW0JHexRfYiVzcGIsaLu3mk7fyU4BHLP5vJx3loIDW2MRHKq4MQ3cp4aLbNwnTUdMxCXrPNfuAjQvhDZc4kbwVamRS8IFII1y8ggAgCOdz2JQtl9vkxqrX-A44pPb9aoM_rKB_y__0zYj3L7h-CG_SpA_bEStHWRzRe4rBDJzTrqn29RI5gSqYFc1qfU-MKahAALmn0YLrNZ0ef0HGSbaPmaIoA3bhX9Q2v9mrWP_tjaP0MuKxDdLPPIiRLtBTnZKzhf05Mm93hdjdi4PlrvEXZu9LI8kSp0BXoKlGUqfSZ9VW2xp8Wz232jjG99AHkje7i5719b0yxccg4GAl4Z-y_ctV5F9ul_FJol_LusC0ThGTd8F1_sAGfy0E3tlWHUL4vjG9Fhs4fw4SPMLuTLESXqPxoZzwagzPkOOUOpsZW1YS5iTgqgNHrE-CG_m_6ZPOkfTBnVJAfTfBWjqsmMSc_kzm3f9sDskqnHzyZ1EgiJItLTdzHZ_gzgt6bNAP90vtiNq8Vc_2mniDTiE5vlpTB4XuJ1_wr7FK-cjSk9pUwX8NhcE53zCTIjVqyhTI0Fl9gk0D6Px-U6Ub4vZQ9xuRbk1Va2gAxSFlho2RZBc1EsLwB_5lGXYJYPWHQ8-qq475g9jTsLVKglOAaBGNHPVvOHrsUjoVjTWOEa72lIVLk69I5hY9nVtbM0QxlPYxAPh8jjNTntrUsoRSFI2R8xQ_u6GlsLjOxBWNA2pZUjDYwziO1xX-LiYGbou7t7lJcP2y2F8HvbQPIEizCa3IAtQ5XLY8QlyzEYB4BqOxa_6iWQiVV-AWYcQXaT6_i-XUaj27hMJToEKzdrjOBF7_LisvpYXgwJBQ_CZrU_dwq6RX97L3JWHyT-Zqv2qZbUKMrVO0pFhRoJEbpmW8pTAl3JzBTO33oaYCF-oVf8StzjaT8Y7imyeuj9NjUkHI9Te8j7mPzsz6MtEwkxJPd1z_1mllkD4MP9ZgOeVay1SpS_XZYf1G_9YL2PGtC2W6OfpD-dm91irlCH2yTuAZY-eSeSFQKU_e-Bsjn85oaXASqyrASJyg2EtBmHwra23YM53eM-BZA_c8sQY-M79bxL9zzS-xedNJQ5OjWomm17pKyAZj2Lj6LjYb1BP7wu3sBQP_KVecLtb50kgnlohVhxkkku6tQ7TiHG2rOHE-hU3ILo5hWxVhAjbkIG5iPeqoEFcvkQfB13a-VLyx8AavV2VFvbwwRz0oRRhMefugby7vIth92ShgjtgItkr2TgNdLmjVBVA6b3RY6TJZXJtG72HI6IzaJvcTC8SVGhB2rdyXkKYMomR02HF26Q55Gtzi5wtoTCV9M60feZ6udaMldBBafO3YCnqewPD2wyf31fwai4BroXuF9d41HD3_kDj25ynPSGxtEWp7MxkK6SkyXR-ZYzMVOvvFk5RJUwdXjgMvQLlsAjsZZMzWuBvYI0yzghE9OIyYguAq3Ar8nIVfOprs4Jl5HsvrVoJN2XG3T6j5oPhlVdkSnIp1Woeb_ZF8wDWF5H8OSe7M9rqLWCSUSMOhmDhvEumMADwwQqz2qCrVk5ZsU2IGVujzAR3B07R-S4-gsQwUWEymWOH1f0QEN-WzzPgl3w-e01gemkrsLChRHTJhDipW5TC_Hd152Hp4ZomGSp1VibnrB6ZQYDajXI7uTZPNhBlLt2X0T1DJVHe0yRxTY2XF4MBRYTi8JihtYQPvk8jIQugjn5UZodJnpJaQ28f955NR9uHEfnf3mKjB5FggaxC6TwtqrOOTljJdidWZOFaDmWocWx4bfGor2sqdHsZi1fV4eZMZjLUVLJa7HiOhqqm8gzhrgbcRuzg4scM3RVQIkCLuc2fnyKn6H_F6SeSpN-pBtoOj0b1V5ew43DkcVtNq3tAH9LAiiSVhhy0EFAYs9qKWcLPtkpPzm7eoJ5YqxgTChjmKq5a7kdjrdZI0lKyH8TEOmYAGhTBF8NmIeZY9awC193Nzw8AXDSY1Bglaoj5MPUXeX5tAIGkZDN-GVJFJD-B1UpzyJKY_gwWaaau0ncVhmUt2WjCC-1u4ejFTJG2Zu0-A9kGMGLQZ5AS49rPwLAaVoRBkrBtviHGJi40agX3pGEEm9wv7X6azUhLC5COge6j9R5AMCdUaMtsLDxdoFBsMxSEeiWHadBoRSxpUTTvPJxEMTPBdTJos7DLOYVR04js8lrBjMmFMpQfg4_FmK0I5B5IflGwQf5WsgDJzq9uTuz6NecybWO5KQiB1NSXH0mi5RtOPz90bQyg8BLvvn2S6ai81aCz0ihRMNOFqRe7QroUIz5QIIah5WM8vquIXWkPWxaJw4S2Ze7jH5OC1lGOG7N_9Uda31WWDdOMi9TaojjG39DU6Ne9SHNPqzGvoB21f-98CfgFw0R58rzBXl2Ka5D0uMX_YuFwqIlw03AKQL0h7CaRI78db2iAuhe-dArSCvxt18RVuc9Wi78nhL7-PpUAud66EkqmuLmtLscRpgFepuDmcfozQtijHVU2JyVcuOgLW23Kw0x6Za-cf92V1pE8AkxGhQ9uRkwIdgbjSM_YEJmdU8Zu3Sz6ytK1bKWpRu9bpzLOkGKyH526uQya-yDxMcavSW_DVFAeAG5y",
                "id": "rs_0eebc99ce6665a77016909294a7f088197905aa9f0ffc0fd96",
                "format": "openai-responses-v1",
                "index": 0
              }
            ]
          },
          "native_finish_reason": "completed"
        }
      ],
      "created": 1762208073,
      "model": "openai/gpt-5-mini",
      "object": "chat.completion",
      "service_tier": null,
      "system_fingerprint": null,
      "usage": {
        "completion_tokens": 946,
        "prompt_tokens": 532,
        "total_tokens": 1478,
        "completion_tokens_details": {
          "accepted_prediction_tokens": null,
          "audio_tokens": null,
          "reasoning_tokens": 768,
          "rejected_prediction_tokens": null,
          "image_tokens": 0
        },
        "prompt_tokens_details": {
          "audio_tokens": 0,
          "cached_tokens": 0
        },
        "cost": 0.002025,
        "is_byok": false,
        "cost_details": {
          "upstream_inference_cost": null,
          "upstream_inference_prompt_cost": 0.000133,
          "upstream_inference_completions_cost": 0.001892
        }
      },
      "provider": "OpenAI"
    }
  },
  {
    "request": {
      "base_url": "https://openrouter.ai/api/v1",
      "model": "openai/gpt-5-mini",
      "messages": [
        {
          "role": "user",
          "content": "Your outpatient, who has PTSD, a questionable chart hx of bipolar II d/o, cocaine use d/o in remission, and alcohol use d/o in remission, at the COH smokes a large amount of cannabis every day and doesn\u2019t think there is a problem with it. He states that cannabis is the \u201conly thing that works\u201d for anxiety, adding that \u201ceverything else I\u2019ve tried doesn\u2019t work.\u201d He has been struggling mightily with insomnia. His meds (\u201cnone of them are working!\u201d- the patient) include sertraline 100 mg BID , venlafaxine 225 mg qD, for mood/PTSD sx, aripiprazole 5 mg BID for bipolar , prazosin 1mg qHS for nightmares, acamprosate 666 mg TID for AUD, naltrexone 50 mg qdaily for AUD, hydroxyzine 25 mg qHS PRN for anxiety , atomoxetine 80 mg qD for questionable ADHD symptoms. The patient is asking for stimulants for ADHD.\n\nGiven the patient's complex psychiatric and substance use history, which three of the following treatment options should be prioritized immediately to address his current challenges?\nI. Counsel patient on stopping cannabis.\nII. Ask patient to request admission to the hospital so he can be detoxed off all of his psych meds.\nIII. Order a urine drug test.\nIV. Prescribe melatonin for insomnia.\nV. Discontinue acamprosate and increase dosage of naltrexone for AUD.\nVI. Start atomoxetine.\n\nAnswer Choices:\nA. I, II, III\nB. I, II, IV\nC. I, II, V\nD. I, II, VI\nE. II, III, IV\nF. II, III, V\nG. II, III, VI\nH. II, IV, V\nI. II, IV, VI\nJ. III, IV, V\nK. III, IV, VI\nL. I, III, IV\nM. I, III, V\nN. I, III, VI\nO. I, IV, V\nP. I, IV, VI\nQ. II, V, VI\nR. III, V, VI"
        }
      ],
      "reasoning_effort": "medium",
      "response_format": {
        "type": "json_schema",
        "json_schema": {
          "name": "answer",
          "strict": true,
          "schema": {
            "type": "object",
            "properties": {
              "answer": {
                "type": "string"
              },
              "answer_letter": {
                "type": "string",
                "enum": [
                  "A",
                  "B",
                  "C",
                  "D",
                  "E",
                  "F",
                  "G",
                  "H",
                  "I",
                  "J",
                  "K",
                  "L",
                  "M",
                  "N",
                  "O",
                  "P",
                  "Q",
                  "R"
                ]
              }
            },
            "required": [
              "answer",
              "answer_letter"
            ],
            "additionalProperties": false
          }
        }
      },
      "usage": {
        "include": true
      }
    },
    "response": {
      "id": "gen-1762208073-hJBmK9QrlWvhdWLpSsNs",
      "choices": [
        {
          "finish_reason": "stop",
          "index": 0,
          "logprobs": null,
          "message": {
            "content": "{\"answer\":\"I, III, IV (Option L)\",\"answer_letter\":\"L\"}",
            "refusal": null,
            "role": "assistant",
            "annotations": null,
            "audio": null,
            "function_call": null,
            "tool_calls": null,
            "reasoning": null,
            "reasoning_details": [
              {
                "type": "reasoning.encrypted",
                "data": "gAAAAABpCSlT8AxqyLGvUjEopoBUsJfdSUcq8pbIBQb1x17sPfm4fv0efDF9DutvFiTxy6sq5CTl34byj8pCH8PFV0vS4TWoBWTp1YPrjQawp50AY2DtsELuOf3uFxJT3VL5fJGpzku_2CsdY7asTbRQB65LXkfw-_DKS_fEpZ8zgqmDPdg6jvuhK4GoLZOkiYMarwLfPr9FfyWu2iWFOnvul3SdTLSD-7ELORV8eEhiyfUIvI4vvI5tyn-Y7EZn9w6rUIsNNDjPLnTF8d787M_lwGexBJ1F_b9TKriMUzXn64aEYzQhKRNz1pImWoAZF3QRbOkYrDoOInAPx0tTwI1OcrnSrf8RUfPYly5lA6blKJEugHeJ0Og9IPiKLnnp3Hj_M1uAcZ7-OrBGmyU72aKOxtnp0jCsxm3gjxotHl6W_4EFtoAZ31cu_RuwOVeZBw8Gsz7vpYGPVSl66h1bY6fYa4rUAKd9n5sv3xT87peBgMccTGaK1DFjcKSdY_st0UpXi18TP2ETZ1ifNUjaMspPMP0zRi58ZVV6OWxPH7gFYalyPjauJf8lIi98r4D5Rzcsy9q6fL04LKWAttFw4tuFQHNtuNmgwI0tkCQHy40nG5i6qZkIVGyKCq_8OazParYPyyz44sSAtXGjqepBghvK1eEfDgj6vYo9yVn_1wonPX0tMx8wvBiqf7iKcA4-tfxNABBSdzNg6ueCrO9Gd41D4Zcn1y0fhproQfTeCVC0nDgq5oxV_XVZSp_mpWh_HCAq-rivbmaFi8lQN9OOpqM1YAaeLD5AWNHaJBGayWcDH5tA6DSTZgd-9nSQkXqpt2OFyWKmTQPcSwy7UtUHYYV08uA3czbChUvvQv6U9Ag_0JxVVmybRg2FGLZTIfb9FwSGIajXTsLSfSKhB4I2G1EL1_6HSuUtI4cfk8IKleDsKYPF7NAI1UZZQRUKJtcfl0-xhHlTrKQ411dA9PFsxAfvzAmBBIlQggcPdmi4HZsC11lqrLeVYiP-NHPL3TiFBHGKPM1L2VARlKQM1a1OIIJj7pU09V4Hg5v83r0Tm1cpyvqhhjxMWc0AhKa_sykEHXCxNWUyoN2nb3H_XE5p8Ivcb_rbx8oxkkTdeZm4txyM5jdwpw6irQSaZn1aUYFl7wmo4__EIPvLJXWY0PlVDpE9WuAttdyz05k-5F2IjtvRtUek06JLiseWJkbE3X_0lQg6SUlBFPuDeGPyeitkV_WPZKkoV4cyKw-NpI_mjkOpwYzitoFgwq12e3A8GMP_Wz7-SvCTkmZKGWuYdnOlQdAXmZpxK0gbbaC9KH_ORkTnmNVt7OHvkHl9ihPuEDoR5uT2oqpDEMQV04h64Xkp7vZmn7JlDsl0m9SGUD24vnHAuyuVwtU8c7qWynKH7-Zr6d2umSON4SI6nnuqn9tkwCtpWLWccTIHtW-bVgd6JH-qLtsjv_Hmgqmq5BUkF0rLQbsgFAlN4IlfVUl8k5gLOkalsEIPBKnX_QOEiWLFOtdfmqsSXWPjo_g1ULZOwYg0yeYd1pyZ9C3yJGkC8oTnNP4-GhCwMb2PwsMD0BrQSPdjHL-gqNBINLHK-yoZ0QQEW5nfQ2lWWBkYwIVNHZE8CdkwJDzJbMPue7dc7ExjFgOQUPL7gntEz0EioNEoEIUt_svSQv5OgQsRZJBDHV84avpaVVbdE4wD-8lh0AvWlmlqTsjEpBDYkkVK1IqkRKZLD3BnSiAMpK8EPuMotz_C6JlX-GJ5fXyHYqCjYdCh8VHXBQz3_oyRePKyRAZrNT1LgFVSbN-OHbAhjixCFTf20cULyCM9DDqqBNK2lf-3hwbeBWKikltbNefdqal3YO4SfCt5Iwr7mKrziEbwGjZPCgT77AB3yDvLwL_upkF3X-32-gsgqH5i-jQxAPq_ORrXDPaBJWuYqyquvdF8qKIaAq2rh8TbtOc3zMaDJo4ii-EUngTyGN10p79kXC5ejIBD4VQC7MwgnM4AWYyPt9U0N7APJbbfq3VgGFfyr6JJo-CzhWLXN5Hk5ptWrAG7hrHezNKPzpWRF5qNV9nIBtuHOCCxggCk8LK-EqxcDIsnoUSbZIEz7qDYScQocjSKDiiqM3whAJ_2eM2KTjTgrfZCMIyI8aeEXrUF324K7s1M8wMg38tRgvDKdFzEigUOHaq2yiz66a6IaDYEiMWARIZgPeSsKLsf_9WIHWYSxJWFayWXcX3XfMrMHQ-C55jsIn6StBLjW60I_ZfNUQlvG8EMvSeVp6OJDW9CI1nkHhuKigA2Jj96U3mUIyHD3jIFfyM1K2zkr8H0HRAnViQDhCxd8gia6hvU4ubTpttRcESRU-8OziYRkeCR-5RVBpxeLgA8WM2WXi2wNCeXYIqy_sYofOY9LTo8t98kmyK4tn7OdI-VJNg5JRG4BOFzNsidKdOU-H5nrr4lTRcTTt8Vx9RFtWHr68-EEB-75x2CcwnlRxlCLZODRV-jr7LcYxIaOrw-y8wG93_Vi8vqVn2vIBArC33fA6OyDpn0EDJDqmNBg_IEeb__w3uI_6XtW_2BwDYL1AAHPkN44UZjzw3e7Fvj7Hmo-7B1m1YbbvCzRI1o1pAlSzUlTB_Vez7x9zyhaKe-4MFNjbYnfLCBG4UiSIXsYRt5B-Pj57NuF5XKu_PvQeoYOssTByfDWbHRTQNWF7f1-fBfKrGdE4OXAoV-0KvQ_AacpFdBbKQNrSjVzrpJb1Ac2-Mrv1XtYGYnDHhHIu92K_6xwDetRfEzOAHlcBSxFlk8vU1fOygaKC2drSgTc14mtvlF6Z9ZoLTC1G4X9FTFaBbSlSofnwqYxseAj05uirymavPoa88npFtBFn8OKekOd9LFCn5hisKDq9A3M4znS--enC4myQlFhCqxZdQHtoI7zN6sFEbAloSKCpnyu-UnQmIPYx3pvKmYHE5YkKOiPmAtttHn6l5fFFbH9BHcUBOlaia0DR8q57CpH0cdUD7_wjbWUxmuOzlgtNhTXiXvm2WQKMC4NBfTOKcr7EpIDfcrZvFnkWw4IbckILxDdbLF86AGeyKLkfECXb9IaBHQlFMXBfefx1_TwbLJKuo0xTtPYifIzI09zD75gnL5-jDFKVP17dUl1pZv7StPacor8gtMQI_zi3eqmyUeDd92ZejMd5MSuy06fTdNqqZbB5SMOBMpPxDIeJWlSV5TW31UeSo3HCsCVUJIUS1RVxxyXUWS1M-GMqxeQpc9JKVaSMWqdPHJEfvsMniF_pbrknJYNMCV_NKyigYvM9D06Tqrhu04xE8By3WKL2mddOPZCJFbUoBQJhNaOQyD2IkyAktuPRTUy17YnUnZC9puAuq-k6iI2p8jVd15-f2hM7lDSkJ0iP8gVvbfd17DSROwqNbowiu0hUQIGa14t9lTse3p6FcJ-hPFmZ57DvGSodjjBBsUxrKi-xUYhuT9tYoKK2uCfndsZ45M34_pyaBMGK1JP4k9u1vpHhcyTAGYKV4ATFu610PXkZC_mOMU9c8P1Y_7qwAYYYb9Z83ysW_GSbR1rytynIMrLfP75ARpLCTINsp_eUvIKR9IgmKPHLFWDLMmY1pKAUrYd4zOIVPlvXsdqX_X_yxzDyil9Q-uuHFYt3YZ5baYeJNxgrxV-jxL7toMI911n5BJ8f1x3k9AfW94sklvMaY-Xp3HEyfQ9MduKVsS0GKAXahm1OqukiuOW0Kl37qQzGCJlPekolNxwHWTqAgXZ9dsclf2bozJJ35sGRIzRzjR5qujZZBytMub30v-wQu08xi7S-jmUBhmElVjgSmFNWhrQqvRUiSh9dQAoLKG3KHyQKH8dMia9IvuPACmcxCBqmFWsnp2wOBgXksXshXUNG8fCKUxrt1I5ktv8KBbUwGnDeM5ZelFx0TEc2jdK13U7TJd7GYTM2i5Zlh3pHDb7LhsW43Nqce6jjhHm-lEB-C-wTy0UCJvs_08vNfl2lleRAGacilqtXz5Hr3LncxHVr_b0hET29vitQdWur_s9rG0O2Uc3l9a_s-f9bHNP0NbgwurDjZMzqYJ-GuXhsMspLMyfAIZQvZjAoCGaEkXLl22uY--qlrGhuMLMALBRUW7NMwdOoDSW9WbT5x28bFAQmYQEl1nypjuGZyVxLTFGmU0HAQWNZpK6BSie1uJhIh56Xux3Zm9LXwDfD_xqejk-b0EEVzVMer9342RCt6OOjAkxLtqiD7_I1P7ecRTsTiAhGvN3ao5S1nFdeoq5c1vY7y66XfV7EDtHR9hihQ0MUMOK7pVy5XuDb7wxzKfqRljLTfh_QD6meRhR9yUiX4XAed5BDNzcVUZzMzFkSOikxSi6oYJHZyyZ1MmW1CnwMIBTwDV4XpmyC5qYQIevm9jmhnL9wN6KVjRGLHaUuStMgQwn_7vISCiIRONqq9qDabxL5kQHFZI_LsdPW1rT2xnMvQaErPJfhUSWtWR6DILEcJC4OyreynPPFwlOTPQ0Leo9Lep0VuBwWV0ltstdTCs9BCUToWKZDLvVk9XbSnBr-SWvPxyCHdf0J2uyq4-AWow7KEuAM3_YzI_T3QdTvHTcN2-WBkz4UAaA5PdP9USjaA4NfPlmNNisV7AhZ4DDpwKzha2nA3i",
                "id": "rs_04b48c9c404bd0c9016909294adadc819588b22dd5b13cd23b",
                "format": "openai-responses-v1",
                "index": 0
              }
            ]
          },
          "native_finish_reason": "completed"
        }
      ],
      "created": 1762208073,
      "model": "openai/gpt-5-mini",
      "object": "chat.completion",
      "service_tier": null,
      "system_fingerprint": null,
      "usage": {
        "completion_tokens": 667,
        "prompt_tokens": 532,
        "total_tokens": 1199,
        "completion_tokens_details": {
          "accepted_prediction_tokens": null,
          "audio_tokens": null,
          "reasoning_tokens": 640,
          "rejected_prediction_tokens": null,
          "image_tokens": 0
        },
        "prompt_tokens_details": {
          "audio_tokens": 0,
          "cached_tokens": 0
        },
        "cost": 0.001467,
        "is_byok": false,
        "cost_details": {
          "upstream_inference_cost": null,
          "upstream_inference_prompt_cost": 0.000133,
          "upstream_inference_completions_cost": 0.001334
        }
      },
      "provider": "OpenAI"
    }
  },
  {
    "request": {
      "base_url": "https://openrouter.ai/api/v1",
      "model": "openai/gpt-5-mini",
      "messages": [
        {
          "role": "user",
          "content": "Your outpatient, who has PTSD, a questionable chart hx of bipolar II d/o, cocaine use d/o in remission, and alcohol use d/o in remission, at the COH smokes a large amount of cannabis every day and doesn\u2019t think there is a problem with it. He states that cannabis is the \u201conly thing that works\u201d for anxiety, adding that \u201ceverything else I\u2019ve tried doesn\u2019t work.\u201d He has been struggling mightily with insomnia. His meds (\u201cnone of them are working!\u201d- the patient) include sertraline 100 mg BID , venlafaxine 225 mg qD, for mood/PTSD sx, aripiprazole 5 mg BID for bipolar , prazosin 1mg qHS for nightmares, acamprosate 666 mg TID for AUD, naltrexone 50 mg qdaily for AUD, hydroxyzine 25 mg qHS PRN for anxiety , atomoxetine 80 mg qD for questionable ADHD symptoms. The patient is asking for stimulants for ADHD.\n\nGiven the patient's complex psychiatric and substance use history, which three of the following treatment options should be prioritized immediately to address his current challenges?\nI. Counsel patient on stopping cannabis.\nII. Ask patient to request admission to the hospital so he can be detoxed off all of his psych meds.\nIII. Order a urine drug test.\nIV. Prescribe melatonin for insomnia.\nV. Discontinue acamprosate and increase dosage of naltrexone for AUD.\nVI. Start atomoxetine.\n\nAnswer Choices:\nA. I, II, III\nB. I, II, IV\nC. I, II, V\nD. I, II, VI\nE. II, III, IV\nF. II, III, V\nG. II, III, VI\nH. II, IV, V\nI. II, IV, VI\nJ. III, IV, V\nK. III, IV, VI\nL. I, III, IV\nM. I, III, V\nN. I, III, VI\nO. I, IV, V\nP. I, IV, VI\nQ. II, V, VI\nR. III, V, VI"
        }
      ],
      "reasoning_effort": "medium",
      "response_format": {
        "type": "json_schema",
        "json_schema": {
          "name": "answer",
          "strict": true,
          "schema": {
            "type": "object",
            "properties": {
              "answer": {
                "type": "string"
              },
              "answer_letter": {
                "type": "string",
                "enum": [
                  "A",
                  "B",
                  "C",
                  "D",
                  "E",
                  "F",
                  "G",
                  "H",
                  "I",
                  "J",
                  "K",
                  "L",
                  "M",
                  "N",
                  "O",
                  "P",
                  "Q",
                  "R"
                ]
              }
            },
            "required": [
              "answer",
              "answer_letter"
            ],
            "additionalProperties": false
          }
        }
      },
      "usage": {
        "include": true
      }
    },
    "response": {
      "id": "gen-1762208073-KFwdTlYvJM8rs48fW8Mj",
      "choices": [
        {
          "finish_reason": "stop",
          "index": 0,
          "logprobs": null,
          "message": {
            "content": "{\"answer\":\"L. Prioritize: I (counsel patient to stop cannabis), III (order a urine drug test), and IV (prescribe melatonin for insomnia).\\n\\nRationale (brief):\\n- Heavy daily cannabis likely contributes to anxiety, insomnia, and functional impairment; counseling and harm-reduction/cessation efforts should be started immediately. \\n- A urine drug screen is low-risk and useful now to confirm recent cannabis use and to check for other substances (e.g., cocaine, opioids) before any medication changes. \\n- Melatonin is a safe, low-risk initial option for insomnia in this complex polypharmacy patient. \\n\\nWhy the others are not immediate priorities: inpatient \u201cdetox\u201d from all psych meds (II) is not indicated and could be harmful; starting stimulants or atomoxetine changes (VI) is unsafe given SUD history and he is already on atomoxetine; medication reconciliation of acamprosate/naltrexone is needed but not as urgent as the three prioritized actions above.\",\"answer_letter\":\"L\"}",
            "refusal": null,
            "role": "assistant",
            "annotations": null,
            "audio": null,
            "function_call": null,
            "tool_calls": null,
            "reasoning": "**Evaluating medication management**\n\nI see that both acamprosate and naltrexone could be used, but combining them has limited evidence. The immediate priority is to reconcile the medications to avoid redundancy, while also assessing cannabis use, testing for substances, and managing sleep. I should focus on these areas. There are potential interactions to consider, especially with sertraline and venlafaxine. Atomoxetine may raise blood pressure too. So, I'll go with option L: counsel on stopping cannabis, order a urine drug test, and prescribe melatonin for insomnia.**Clarifying medication priorities**\n\nI need to explain that cannabis may worsen PTSD and insomnia, and it could cause cognitive impairment. The urine drug test (UDT) will help confirm cannabis use and rule out other substances like cocaine or opioids before making any medication changes. Melatonin is a safe first-line option for insomnia with the current meds. I don't need to prioritize inpatient detox or stimulants, and the acamprosate/naltrexone discrepancy can be addressed later. My main priorities are I, III, and IV. I\u2019ll return JSON with the answer and answer_letter \"L\".",
            "reasoning_details": [
              {
                "type": "reasoning.summary",
                "summary": "**Evaluating medication management**\n\nI see that both acamprosate and naltrexone could be used, but combining them has limited evidence. The immediate priority is to reconcile the medications to avoid redundancy, while also assessing cannabis use, testing for substances, and managing sleep. I should focus on these areas. There are potential interactions to consider, especially with sertraline and venlafaxine. Atomoxetine may raise blood pressure too. So, I'll go with option L: counsel on stopping cannabis, order a urine drug test, and prescribe melatonin for insomnia.**Clarifying medication priorities**\n\nI need to explain that cannabis may worsen PTSD and insomnia, and it could cause cognitive impairment. The urine drug test (UDT) will help confirm cannabis use and rule out other substances like cocaine or opioids before making any medication changes. Melatonin is a safe first-line option for insomnia with the current meds. I don't need to prioritize inpatient detox or stimulants, and the acamprosate/naltrexone discrepancy can be addressed later. My main priorities are I, III, and IV. I\u2019ll return JSON with the answer and answer_letter \"L\".",
                "format": "openai-responses-v1",
                "index": 0
              },
              {
                "type": "reasoning.encrypted",
                "data": "gAAAAABpCSldzonn_jYjaPC-uyZVFO8_XNFstDL3eX6ewCULedx6Lwt2H-oHYKS0kJAmXAQ1tMd-AICP_AJ_mc9iTDE3xaJiaPa6g-j7uuVlLcUyqQ4rnsEecVLq7MSpl0CJ2QWLD1skMtXjTdlDSHstiJebfu8OVSAUof-_MiYhEU0409yO5T_yK5rHW_e-z3ODeOPi7Ic63SX4P9yeo9karCntyYAvF_3-v7Ys9CvoTo6Y04fvhzxherrtqhaqxyI2lDQXVMzaiIZvAGcpW-vPwa5GOyaauiox6p7gKvZ6x_HYwXtd6bd5QWuv2BOtc3ybl-9qNmHoYdfWrCfGABiYi5Z57Xk_NYj3tuQO_hnRU6oJQC7_kbie_-WdF37B_64pNVCiyoSuvWILc5C95nygyFI8n5hsiATorLyc9yV7OkpfZItW5nKbFxl8gMXbIdMiwBz_nHgFVC7crxRDezAYf-V_AX8baEHtDf259bF_3avoYrMwU1T5rpCCx4y7SObcP_UcvYRpCB19cct07lbnwCflxhAkugv_Kbf-Gl-4szzsBcATbE7I2bvFWZDXwF7818am8tYu7-k0PfdyUasEc-NJHsVMC_jW_B-TTfUftVqsuOfzVKSeqtDIz-9hXFdvSn8iyCUB5EMcjK3geb8C2HZtrsZ7wQnFYTVnM5x5Bkt5SKgCM3zAT8f7EcAR5Z3BeMrg91hG8ZkSUxfz8nj6eFrmejqtz_3RS78RKJTbxn8JCQ3qd02e7FFke2kzCA_JPGxWYbzuHU4Mryk6_hXUrLk-dATB1nN3FOHHDsZYV4-onWMQihPY-rXdivWkv07aJV3hCETKAZ20lo6G-yb2Q7YzOEQa8JfKSw0RVWxrkxgZ7n-a9KW76frHBoHM2MWPrdXscew8RbmZWglMojZEObozro6t7zJldo_w7kYXlQ4_qaJeWPZSpleq6UqzIr57KEas2BMoiTOoiBEa-am0Zglwx-oAQD5k0ZwIQt7inVyaFJaAVLURmeYDXQfeEfP3luypf6LynMZBUvi4JDfNlcfSeOdFZOs6HMzugHB_zZRoFUOuecvfPEvw-1eEfQztWuJ10PtvA15PEN7mGOT_duPHC9L1jSVA4AoPUv-QCYp4MCYxFy4t6l9hJvv1duDH5Ca01GqAns47gJNQWPOgO2hmy1aG_HMNvUaZKAJSPNI0TZr72XpD9EG-sQ-ViLx3JPHdudITt5DaBclK_HpSuIBxLcNU7DsEp2_AcGlM9257_QxWtbjw3duTyIeKU4-oCHoH1JZxZdIW8VLlL72YW3DXt3FqawgOuNIR4NGIY0JLGW_XWMziwzhsykAg6wyLBma5CeJg2s32RD9laEQInQnaIuC1_FZLv5h29aPuP2Phk-kemEw7oop_8F-OpNQdVG-VTyAUu8zPgocyXdEHLQ-J8itxAvGDrMeH4KtX8pzL_Pi3FQz_KjBSYjbobHQKIsFKhCntjZkdEIKFGFZAor8Ck1S8vxOFbJvHZ9cK33_34DJ399_87gN7Dh5erZCQAB89Hjx9K-EvMzMXuSwdSg4Op550B-SQ9e0zYr89a9j3Z2ZskE0GP_TGdur3ctZXVoPTWL5Q272lSX3dsrCJgsRCLfxs4mzacqUP8rzgYVa_Mkcho3QzwObJGhqJDJDwTPs74L_IfTf0AHtxZwfDcC35pAsvlb_hRYclOHIx6SztPts-j5O3MkK5mff0yeSmlJj6pYUAjGY0yQ9wVRAanwdhm1tqW_7HnnYM0LKPAVLi6cspwm96azHko6y49DyJqvOcUbnrT60FIp85K3o1Afcu_vjEFqzUpk18-Ewh4LAOST-u9T17CbIYzV3-bbejch1OJ_BCDb398mECzoDMU39RCRCVjPemnWodJ9J5u2bSozLjD3geBjR7BC7UyOILuqSwgMvWrGarr3FjhljphFv57Rp4MAi1Lw2Ng8q759bD7TLeJSnLuTh5bGtlarmGs2M9irg5MazeimUvF7H37fHN3NgVpxrNd48BmVbwoyI8CVJxKPogr-e7Dw8D5hV32x7y4i61qEAcPpTsL9r9i3JuStWCCsNWtWyZ-Sa1afQSCb8KOdf_DGHsQF9vF3iS2HB5y_Dh-ghfPzEFHbZiq320QJ1JOeCeVs3krwtDCHDTOP7E0LI6YQ-xts4InNhisxd6hhoqNGXW_PPHL5oz3B13LwkS2XsYZSWoPicuTwtiy6rHEmHn4xEEdR7ZanIaAspAv29rtagmEuwOm4OAxTfE7k-MwOY7ZaBnQFyLV7CfUxd8_9syNztNbWq09jhszem129wnRHqRFJ4Pnnm8GJWHzunmYVqRuUId2gTeG5sAXppbQ3Agz7lMnBjIRVlJFRUgxcy8fvfekE59jpIaypNWzoRHwe6cxDABbiJtHMAD6JHEAqmUdLE1S8Bt1kAWcnK3M8cg37xipFflADR7WKoa7yYV4E6vojjeMjHNcAXAsUHFgsZ91M_ekCAp4EKjRw-e3XHtdUvFxkgYY9nvEvB08_gQX6Obr840ABxLaT8P9oej9LeC-OjOxvbKKIUAkTZbIVTj2zyDJ1AvZaK2sCqB65VLORGpLW_9_SZJsYxgtfJA3xrdwmj7hGnbuHIZ33JllI753OqRuBIdCd6NczXbQIUUku10PJMerp4E0x4VM2JDD9nPkMAAFwjePhVqNuWeT6x3WBzFCtO-C-TxIUikTHBiFPKOPNJvxPlNJwniSSvA2i3cUdDJnlcIO3Tvqj7_NdpiVtXIc_ITlj5wmWtSlyQQrIpAtSVeDw8swKljWoFbYvAIm8TB3_whvkPUIaomGwavGtgFHJA-I9esBM2RSshi8YtLrNILOXOYXN2yz0s4hTlGSFV9uA5ZqaV2SJWcpfH7xid5f990sz72kISF5LsV6yi2pQXFFcUBIyLwHtqmTynaPYI6WRra1wNIFFnVPW99R2bK8NTJOjxNKEJh4WxWhpdX8NDrsnw_nsrdtDjhh3vKCWy87UXJWM1tHlh4Tm_kHs4B0zmsfNkviQ9P5gvoZh_RhG1UX1o_s-yxvfg5fxxPY30LmPZLEjRSM9n_XyLrYtJt8Y6xJo5o5MhJ6PPoyXGCWgOIWR_rTpP9yfojiNercHMBTA69hQF-OdQtlwkuOf3Eo0LbfuApynyXAGgoSvEAHGZyGwYKIsgRmW53UpRY7j8Fv6aBYHj3glEFzbmKt20-QHBjZcRmbfoaHI5AAJv1je-KyAfH9mmuVLew2ANm36sb6s_CmF9UoehtEw43kBPHiJSb3I3EOG0NMOdZDNXMPz65VYR0exbYvPZp_wcpbFbLckFfWwpZmJzmq3Qy_lmc_nSOUl-7kdUS-Qt_hLWrd2-teLmDQYjLJsqZmVNYZJPyXo6B5KRdzLdI8NpNbcWQlxd60amb7N1iU1kqT0-VzBpPBjR_rW-wl3V9jY1Rx3ubGZTkUrbMY68Vu5mb60zc7bmfYEfMY68F8DED1vyZUI42a6zAOu255GZjv4ptJDC_S2sLp6cGNNRZrVhzw1q6jxTqWCSTYPbAYw0eTybroSBNIS2Jgp_cLkK5CJ-gClad0PeuOpQBmuVp6y93J1URHtdh7uqeJVg35FBJ1CYwR1ZMXfT-bJ0RzUOackO5nXoQLtfCaPADbDoWHkQfFeF9dBgyclNExKKUyLh7NZDTSenVwTc_W1u96CSlulH-1v4ufq8piL4gMA70wV6so8BnRJMLTM2tFZV46ud7QCgdt9euEoWXNhJp4TSVMS_maTBprbSyte9c0G6PbGlISGkqyFzhcQt3-On7s2vHSxRsP2mJ2e75xyt9Dm5hQR6zzGqpw92o4K-BwhqUSG4YTEYqk28Jz1THbFDpKysAMqLrNmaSwT32SImCwdZkJyOFjE7CNe-_oqLMeNEZ-huBXhHAy37UfAYKxHz_OMREJkQPBrjfRfKOuA5NFEm5nYnefbki9gEmABKJOrOJeatptSwerDRv_1YuwE2EKegnhRk7v1VxZl80aSUYD6IG_AJCuDrHyWWI0nUIpzGqu41IkXNqiWwO0_OYP2zfUdthg631ajfWWkDGOW8Lv_8NdJbXh85VlHFwAUZkmSPen9-ENKrrI_wBU_q0xeLZFBiqL1tlYd3COq26rxoUd3AY5V8unuyWIKJ_WOI3_jbB4KH6JYrLMG9nLKZQI4caMWJgbfKKOWSTQXWJephjQ_uYH1gTuwwRK5Ubdl6__Vxt-dUlvzPWZE4KoI9yNfQUEMtdcoidbwwYpPYjLwesltoH1NRsy2wnb3llSIJDvP9VrqiveMBAmIS_d0hGX1igLuFzBC_H08bpWfPykSSmFgmgB4GRRQduVN4O7sx2_AEPnfy_lHLgfKkI-UPE-OSLQpSFx76E9iRV78Y819R65NnYzmv7gJDgJ7sB6ynv7usmCOrIN1waViuoe0R3YLtUp4MV7ZnNfx-ojA3Bpzt1VJYd2u8wiLTmI5MPGX3etlltk-9Vuqh1G1wzdZ_X6lcs2rUYVKeuej3kiXLwUa5SLaas2umFPYh_Ds5Ihsy77wbyK8RM3SxFeVF624bRPcqFGRmZUedW0YBJ1C42Pe3-QXKEzn8FlZyz0VmHr4DLnnidSExzK6CW_NHBvZyFpTtLP_D7YOaVu4Wd9sLuTQF6MdXF2qjMMSBBkTIDzuCMyjaFV3Ltdkk4OQPNjcHlqvlKH4jdfRJUpBxmkw5r3JjaFGWSUGgkZtp8VPKNYevBiZXu-yd71Q3M2--8Ns1zMl5WMbesONWXIhm03U-8bOPC01PNUvp1myFPtVb1TDF8ZGKc8QXFV6a5vyJXKttqEUnWeq93kVg3rFYqAckQO9OvuWCufJ4ShOfvSiBydSVyr4qoXHVPuXmUWa8PqjMXtIAoRwKKrljDbLVbjuHC6JCYPTLEMCL7WSANUfj5R5TVHXwJAZJ3xA7kY29yUezaPf5Y3kTlPiW2nQcgmHV1et4Nrnt3DIrgl4Iih24Arq-XI_vZVjuyJeTOTPSNwuwD6Pxyp8rtjaEoYUJ0ISQ4rwj1VRAX5rSnneZpqkFo9fP53-KCFoRpsFmtSIqFQ8caYQ5_XFoEKgEvU_Ppw6ZIEAwXS8D857t14mCpvbUp5aryaOUG0vOW70yJ1h_kOpB7N0aAA1gOMAtNvs-x40fEvSX1xL02j1SMuSN6NHAVZaiNP4N2AZjYP3342u0_udu-KVua70f8CvOuXBmN6x2zpOeXLakCV9osfOGsdSFHHHmKtPffnNgWrmP4XpbE3-qMTyUdCLy_4laOXFfy7XUID8Gth_d0TqpWjV-YFN4GDFewivT8V1z9YaV-jPgtjsq1Jo9Pdsc2NQqnYLHm7xFndCwOHSgr4jJQUImj_WklOruKVn_psR_Ug98i1-oIAQA5VurOGt_JvQ_mg2ftuBPaSsFEYX1HhgYTnuvAj5Oo_25GVNErG968m384F2gBtav8oqb1ngQ-phTRaYOPPUxj7oRODFBTtFXU_wJOfMJsT1NCTg94ocQ5IQW8b_ec01y8XzC4rPG5aU9p8gkZToZhYSfDpKodQQr2d8HWLplw4AvYPICnjh2sUk3qH0qzMyD9aFzXW06oRbOiutZWkY4Skhf2peUA065v_3jtC-JSmxKCHPOtXxMaUOhDaWUtSpngIL2hrdNh94Zmd9Vxfj6sCsUVCSdns6FmwmDqJwS39d1O3DyD8YueNJgW0B9z_87pzVEjS-AUTYVRGXLetbJLZpfduJC-OeoshSWfbZBRKyONOMykXdlqXYhL8iTJFVEqa-GNcBNxeF3siZJKVu7MYy-OWWx49v_tSQE4BC4tMOAdHG8fva51XtjX6pJ1d2bJyr22AP5BTxwdA8dTw7Ll3e_P7JL2KalbKI15bfcGjXTiyqpDwEd5cpI2V2WGVY-x6hFciRnj4_jzEWhnN948Mo7DkG06XsXi_hbnuHjyXR72X8ZsODWYOgw0RdtSrggxy-mj-3QhV_UuBxcScIeu6SIvjG7DPMtfMhZDoNnUgzioNfDoYMx_Xl5VxzukwDkrodTgTSbDWr7_figoGubj9Rqy9jtSZqyhrrxI34-jRWr8Ed9Co5jDGXEqBigPM0uq6X-1w_hziYuub8PL3Qh3wydApzjnHD5qMAYCl_HpSMLKl1eN3XkATf4Whc7f5Cu0qdLdh-0pjyKXI9XZPGBcZ2EdrPtPqy_n8eHj7wY4Sb30m9tVq8lNTYNdfX9QaMkn9ZWjKdcaLMvHZ_OM_naD-fLyiWvJRRI0B42E1DeZNd7bFWEKWxTXvhvBwH6iLyBu7fkMX0DjSTPnB29ZmWoZU5zbIWy9OhfF4RraW22t6jSMVeaXRyzj6_crkoQ6inCBw5Ds5F5fKIm8haI4mta-h87aIFBuacM8W2ZdVrpW8sLwlvcXsbrCVz7-nFXSsSKYXa-XLKXfHNZJxeLmmmlkEgDAU77AsNQGeZxsWmtGv56NMjR3oGjpoWvMaBQWeT6qOR0o9Q3FCOKwSSuhzurVE9PUgTo6W_C5SR3x7LgiFqGTWrbuCxEYx_MHHyFDFyEtwAnGVTgw9HNpTu_bEcgrBwsRH0pEDD1drcIOO5r8ilPS3HU0p9w8lPKBt_54DRwp32FpJ0OO-dSDIoKku-0Vzhs5j3S6PNArJXvkoKQMwMnugC2EeZlMBu-1sWzoufR1zMqTUtxZKDn47x3V4FSorsnQEHECobc=",
                "id": "rs_0ad2e5309e30a283016909294a67f88197824e9b458b677c3b",
                "format": "openai-responses-v1",
                "index": 0
              }
            ]
          },
          "native_finish_reason": "completed"
        }
      ],
      "created": 1762208073,
      "model": "openai/gpt-5-mini",
      "object": "chat.completion",
      "service_tier": null,
      "system_fingerprint": null,
      "usage": {
        "completion_tokens": 1188,
        "prompt_tokens": 532,
        "total_tokens": 1720,
        "completion_tokens_details": {
          "accepted_prediction_tokens": null,
          "audio_tokens": null,
          "reasoning_tokens": 960,
          "rejected_prediction_tokens": null,
          "image_tokens": 0
        },
        "prompt_tokens_details": {
          "audio_tokens": 0,
          "cached_tokens": 0
        },
        "cost": 0.002509,
        "is_byok": false,
        "cost_details": {
          "upstream_inference_cost": null,
          "upstream_inference_prompt_cost": 0.000133,
          "upstream_inference_completions_cost": 0.002376
        }
      },
      "provider": "OpenAI"
    }
  }
]